Outcome Health inks deal with the feds, closing fraught chapter for POC company

Gavel court room lawsuit judge
Outcome Health reached a final non-prosecution agreement with the Department of Justice to close out the agency's investigation. (Pixabay)

Outcome Health’s skies are finally clear. The Department of Justice (DOJ) decided not to prosecute the point-of-care marketing company after more than a year investigating misconduct by now-former executives and employees.

DOJ inked the non-prosecution agreement with Outcome not only because the accused employees are gone, but also because of Outcome's overhaul of its compliance and campaign-reporting policies and restitution to clients.

Outcome will not face any fines or penalties. The company has already paid out more than $65.5 million in make-good with clients. It will also maintain $4.5 million in a fund for any potential future claims, said CEO Matt McNally. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

RELATED: Revamped and renewed Outcome Health looks to spark change in point-of-care industry

“This was one of the final hurdles that obviously was of concern to some of the manufacturers that haven’t come back to our platform to date," McNally said. "A lot of clients have come back and a lot of clients wanted to see the new compliance firsthand, but there were certain manufacturers who wanted to wait to understand what was going to happen with the DOJ."

He added, “For us, this was one of the final pages of the past and previous administration that we are very happy to turn.”

In the day since the agreement was announced, supportive messages from clients and others have been pouring in, McNally said, and he anticipates that more pharma clients will return to the in-office advertising platform.

RELATED: Outcome Health makes peace with investors in $159M deal that pushes high-profile founders aside

It’s a welcome change for Outcome after two years of turmoil that began in the fall of 2017 with accusations in the media about some employees misleading advertisers. The allegations spawned a lawsuit and put the company's finances in turmoil.

Outcome has since worked to rebuild relationships with pharma partners, investors and its own employees. The effort has included new executives, new directors on its board and investors.

Outcome recently launched “In These Rooms,” a digital and social media campaign that shows the joyful, mundane and heartbreaking experiences of patients in doctors’ offices and waiting rooms to highlight the importance of those spaces in peoples’ lives.

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.